17.65
5.82%
-1.09
Calliditas Therapeutics AB ADR stock is currently priced at $17.65, with a 24-hour trading volume of 6,136.
It has seen a -5.82% decreased in the last 24 hours and a -19.95% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $18.41 pivot point. If it approaches the $17.13 support level, significant changes may occur.
Calliditas Therapeutics AB ADR Stock (CALT) Financials Data
Calliditas Therapeutics AB ADR (CALT) Revenue 2024
CALT reported a revenue (TTM) of $135.65 million for the quarter ending December 31, 2023, a +237.28% rise year-over-year.
Calliditas Therapeutics AB ADR (CALT) Net Income 2024
CALT net income (TTM) was -$26.43 million for the quarter ending December 31, 2023, a +60.89% increase year-over-year.
Calliditas Therapeutics AB ADR (CALT) Cash Flow 2024
CALT recorded a free cash flow (TTM) of -$31.04 million for the quarter ending December 31, 2022, a +42.44% increase year-over-year.
Calliditas Therapeutics AB ADR (CALT) Earnings per Share 2024
CALT earnings per share (TTM) was -$0.983 for the quarter ending December 31, 2023, a +61.74% growth year-over-year.
Calliditas Therapeutics AB ADR Stock (CALT) Latest News
Novartis (NVS) Presents Positive Data on Rare Kidney Disease Drug
Zacks Investment Research
Palo Alto Networks Issues Weak Outlook, Joins Teladoc Health, SolarEdge Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Benzinga
What's Going On With Vera Therapeutics Stock Today?
Benzinga
Why DouYu International Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
NeoGenomics, Energy Fuels And Other Big Stocks Moving Lower On Thursday
Benzinga
Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
About Calliditas Therapeutics AB ADR
Calliditas Therapeutics AB (publ) operates as a biopharmaceutical company in Stockholm, Sweden. It focuses on identifying, developing, and commercializing pharmaceutical products for patients with unmet medical needs. The company's lead product candidate is Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) also intends to take Nefecon through a global Phase 3 study to commercialization. The company was founded in 2004 and is headquartered in Stockholm, Sweden.
Cap:
|
Volume (24h):